Login to Your Account



Protagonist’s Series B Draws New Investor, $4M for GI Pipeline

By Catherine Shaffer
Staff Writer

Thursday, September 19, 2013
Protagonist Therapeutics Inc. added a new investor, Pharmstandard International SA, to its previously announced Series B financing, boosting its raise by $4 million, for a total of $18 million. The funds will support Protagonist’s pipeline of orally stable peptides for inflammatory bowel disease (IBD) and other gastrointestinal (GI) disorders.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription